nach oben

Drugs

Erschienen in:

01.10.2010 | Leading Article

Thrombin Receptor Antagonists for the Treatment of Atherothrombosis

Therapeutic Potential of Vorapaxar and E-5555

verfasst von: Sergio Leonardi, Pierluigi Tricoci, Dr Richard C. Becker

Erschienen in: Drugs | Ausgabe 14/2010

Einloggen, um Zugang zu erhalten

Abstract

Platelet activation, achieved through a variety of surface receptors and biochemical mediators, represents a key event in the pathogenesis of atherothrombosis and its clinical manifestations. The major pathways involved in platelet activation are triggered by thromboxane A₂, adenosine diphosphate and thrombin, with the latter being the most potent of these agonists. Despite the effective inhibition of the first two pathways with aspirin and several generations of P2Y₁₂ receptor antagonists, respectively, the recurrence of ischaemic events in patients with atherothrombosis remains high. In addition, there is a growing concern over the safety profile of increasingly powerful antiplatelet drugs in terms of bleeding, which has tempered expectations of newly developed compounds.

Thrombin receptor antagonists are a novel class of antiplatelet agents that inhibit thrombin-mediated platelet activation. Preliminary data indicate that these compounds may have the potential to improve ischaemic outcomes without significantly increasing the bleeding liability. Currently, two agents of this class are under clinical development: vorapaxar (previously known as SCH 530348) and E-5555. In this review we discuss this novel class of antiplatelet agents, focusing in particular on their therapeutic potential.

Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006; 99: 1293–304PubMedCrossRef

Roth GJSN, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975; 72: 3073–6PubMedCrossRef

The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494–502CrossRef

Wiviott SD, Braunwald E, McCabe CH, et al., TRITONTIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15PubMedCrossRef

Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045–57PubMedCrossRef

Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361: 2330–41PubMedCrossRef

Mann KG. Thrombin formation. Chest 2003; 124: 4S–10SPubMedCrossRef

Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258–64PubMedCrossRef

Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A 1999; 96: 11023–7PubMedCrossRef

10.

Chackalamannil S. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. J Med Chem 2006; 49: 5389–403PubMedCrossRef

11.

Gurbel PA, Tantry US. Combination antithrombotic therapies. Circulation 2010; 121: 569–83PubMedCrossRef

12.

Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084–9PubMedCrossRef

13.

Leon MBBD, Popma JJ, Gordon PC, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting: stent anticoagulation restenosis study investigators. N Engl J Med 1998; 339: 1665–71PubMedCrossRef

14.

Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849–57PubMedCrossRef

15.

Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354–62PubMedCrossRef

16.

Eikelboom JW, Weitz JI, Budaj A, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2002; 23: 1771–9PubMedCrossRef

17.

Cattaneo M, Zighetti ML, Lombardi R, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A 2003; 100: 1978–83PubMedCrossRef

18.

Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706–17PubMedCrossRef

19.

Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 919–28PubMedCrossRef

20.

Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51: 3061–4PubMedCrossRef

21.

Serebruany VL, Kogushi M, Dastros-Pitei D, et al. The in-vitro effects of E5555 a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost 2009; 102: 111–9PubMed

22.

Vu TK, Hung DT, Wheaton VI, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057–68PubMedCrossRef

23.

Soto AG, Trejo J. N-Linked glycosylation of protease-activated receptor-1 second extracellular loop. J Biol Chem 2010; 285: 18781–93PubMedCrossRef

24.

Gandhi PS, Chen Z, Di Cera E. Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. J Biol Chem 2010; 285: 15393–8PubMedCrossRef

25.

Marino F, Pelc LA, Vogt A, et al. Engineering thrombin for selective specificity toward protein C and PAR1. J Biol Chem 2010; 285: 19145–52PubMedCrossRef

26.

Kahn ML, Zheng Y-W, Huang W, et al. A dual thrombin receptor system for platelet activation. Nature 1998; 394: 690–4PubMedCrossRef

27.

Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol 1995; 75: 12B–7BPubMedCrossRef

28.

Xu W-f, Andersen H, Whitmore TE, et al. Cloning and characterization of human protease-activated receptor 4. Proc Natl Acad Sci U S A 1998; 95: 6642–6PubMedCrossRef

29.

Hirano K. The roles of proteinase-activated receptors in the vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2007; 27: 27–36PubMedCrossRef

30.

London FS, Marcinkiewicz M, Walsh PN. PAR-1-stimulated factor IXa binding to a small platelet sub-population requires a pronounced and sustained increase of cytoplasmic calcium. Biochemistry 2006; 45: 7289–98PubMedCrossRef

31.

Keuren JFW, Wielders SJH, Ulrichts H, et al. Synergistic effect of thrombin on collagen-induced platelet procoagulant activity is mediated through protease-activated receptor-1. Arterioscler Thromb Vasc Biol 2005; 25: 1499–505PubMedCrossRef

32.

Riewald M, Kravchenko VV, Petrovan RJ, et al. Gene induction by coagulation factor Xa is mediated by activation of pro tease-activated receptor 1. Blood 2001; 97: 3109–16PubMedCrossRef

33.

Schuepbach RA, Riewald M. Coagulation factor Xa cleaves pro tease-activated receptor-1 and mediates signaling dependent on binding to the endothelial protein C receptor. J Thromb Haemost 2010; 8: 379–88PubMedCrossRef

34.

Lova P, Campus F, Lombardi R, et al. Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin. J Biol Chem 2004; 279: 25299–306PubMedCrossRef

35.

Dubois C, Steiner B, Meyer Reigner SC. Contribution of PAR-1, PAR-4 and GPIbalpha in intracellular signaling leading to the cleavage of the beta3 cytoplasmic domain during thrombin-induced platelet aggregation. Thromb Haemost 2004; 91: 733–42PubMed

36.

Swift S, Xu J, Trivedi V, et al. A Novel Protease-activated receptor-1 interactor, bicaudal D1, regulates G protein signaling and internalization. J Biol Chem 2010; 285: 11402–10PubMedCrossRef

37.

Andrade-Gordon P, Maryanoff BE, Derian CK, et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A 1999; 96: 12257–62PubMedCrossRef

38.

Chackalamannil SDR, Asberom T, Doller D, et al. A highly efficient total synthesis of (+)-himbacine. J Am Chem Soc 1996; 118: 9812–3CrossRef

39.

Doller DCS, Czarniecki M, McQuade R, et al. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett 1999; 9: 901–6PubMedCrossRef

40.

Pharmacology of a selective, orally active thrombin receptor antagonist, SCH 530348. Report no. 46293. Kenilworth (NJ): Schering-Plough Research Institute, 2004

41.

Chintala MVS, Kurowski S, Sabin C, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in cynomolgus monkeys [abstract no. P579]. Atheroscler Thromb Vasc Biol 2008; 28: e32–149CrossRef

42.

Kosoglou TRL, Tiessen R, Fales RR, et al. Trap-induced platelet aggregation following single and multiple rising oral doses of SCH 530348, a novel thrombin receptor antagonist, in healthy volunteers [abstract no. PI-40]. Clin Pharmacol Ther 2009; 85 Suppl. 1: 40

43.

Kosoglou TRL, Kasserra C, Young S, et al. Optimizing dose of the novel thrombin receptor antagonist SCH 530348 based on pharmacodynamics and pharmacokinetics in healthy subjects [abstract no. PII-42]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S55

44.

SCH 530348: rising-multiple-dose safety and tolerance study of SCH 530348 in healthy volunteers [study report for protocol P03450]. Document ID 2926091. Kenilworth (NJ): Schering-Plough Research Institute, 2006

45.

Jennings LKEA, Becker RC, Reyderman L, et al. Thrombin receptor antagonist (TRA; SCH530348) is a selective, potent inhibitor of PAR1 activity with predictable pharmacokinetics [abstract no. 3010]. Circulation 2007; 116: 674

46.

Chintala M, Kurowski S, Zhai Y, et al. SCH 530348 Is a novel oral antiplatelet agent selective for protease-activated receptor-1 (PAR-1) receptor subtype without partial agonist activity. FASEB J 2009; 23: 757.6

47.

Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800–14PubMedCrossRef

48.

Sambrano GR, Weiss EJ, Zheng Y-W, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001; 413: 74–8PubMedCrossRef

49.

Hamilton JR, Cornelissen I, Coughlin SR. Impaired hemostasis and protection against thrombosis in protease-activated receptor 4-deficient mice is due to lack of thrombin signaling in platelets. J Thromb Haemost 2004; 2: 1429–35PubMedCrossRef

50.

SCH 530348: influence of chronic renal disease and hemodialysis on the single-dose pharmacokinetics and pharmacodynamics of SCH 530348 [study report for protocol P03464]. Document ID 3303095. Kenilworth (NJ): Schering-Plough Research Institute, 2005

51.

Reyderman L, Kosoglu T, Tseng J, et al. The effect of food and antiacid on pharmacokinetics (PK) of SCH 530348 in healthy subjects [poster no. PI-42]. Clin Pharmacol Ther 2009; 85 Suppl. 1: S21

52.

Goto SYT, Ikeda Y, Kato K, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH 530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010; 17: 156–64PubMedCrossRef

53.

Matsuoka T, Kogushi M, Kawata T, et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury [abstract]. J Am Coll Cardiol 2004; 43: 68ACrossRef

54.

Kogushi M, Kobayashi H, Matsuoka T, et al. Antithrombotic and bleeding time effects of E5555, an orally active protease-activated receptor-1 antagonist, in guinea pigs [abstract]. Circulation 2003; 108 Suppl. IV: 280

55.

Kogushi M, Yokohama H, Kitamura S, et al. Effects of E5555, a protease-activated receptor-1 antagonist, on the inflammatory markers in vitro [abstract no. PM-059]. XXIst Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6–12; Geneva

56.

Kai Y, Hirano K, Maeda Y, et al. Prevention of the hypercontractile response to thrombin by proteinase-activated receptor-1 antagonist in subarachnoid hemorrhage. Stroke 2007; 38: 3259–65PubMedCrossRef

57.

Morrow DA, Scirica BM, Fox KAA, et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2°P)-TIMI 50 trial. Am Heart J 2009; 158: 335–41.e3PubMedCrossRef

58.

The TRA·CER Executive and Steering Committees. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial: study design and rationale. Am Heart J 2009; 158: 327–34.e4CrossRef

59.

Létienne R, Leparq-Panissié A, Calmettes Y, et al. Antithrombotic activity of F 16618, a new PAR1 antagonist evaluated in extracorporeal arterio-venous shunt in the rat. Biochem Pharmacol 2010; 79: 1616–21PubMedCrossRef

60.

Planty B, Pujol C, Lamothe M, et al. Exploration of a new series of PAR1 antagonists. Bioorg Med Chem Lett 2010; 20: 1735–9PubMedCrossRef

Titel: Thrombin Receptor Antagonists for the Treatment of Atherothrombosis
Therapeutic Potential of Vorapaxar and E-5555
verfasst von: Sergio Leonardi
Pierluigi Tricoci
Dr Richard C. Becker
Publikationsdatum: 01.10.2010
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 14/2010
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/11538060-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 14/2010

Telbivudine

Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections

Lopinavir/Ritonavir

Capsaicin Dermal Patch

Aztreonam Lysine for Inhalation Solution

Prevention and Treatment of Menstrual Migraine